Can I Take Melatonin with Retatrutide?

What Is Retatrutide and Why Does the Combination Matter?

Retatrutide is an investigational single-molecule triple-agonist targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR). In the Phase 2 dose-ranging trial published in the New England Journal of Medicine (N=338), participants receiving 12 mg weekly subcutaneous retatrutide lost a mean 22.8% of body weight at 48 weeks versus 2.1% on placebo [1]. That degree of weight reduction is among the largest reported for any pharmacologic agent in that time frame.

Because retatrutide works partly through GLP-1 receptor agonism, it shares metabolic effects with semaglutide and tirzepatide: slowed gastric emptying, reduced appetite signaling in the hypothalamus, and enhanced glucose-dependent insulin secretion. The glucagon receptor component adds thermogenic and hepatic energy expenditure effects that neither semaglutide nor tirzepatide produce.

Why Sleep Aids Get Asked About Often

Patients starting any GLP-1-based therapy frequently report changes in sleep architecture. Appetite suppression, caloric restriction, and rapid weight loss can all alter sleep quality during the first several weeks of treatment. This drives many people to reach for melatonin as an over-the-counter fix before discussing options with their provider.

Melatonin is one of the three most commonly used supplements in the United States, with roughly 4.6% of adults reporting use in national survey data collected by the CDC [2]. The assumption that it is harmless because it is "natural" can lead patients to skip the conversation entirely.

The Knowledge Gap Around Retatrutide Specifically

Because retatrutide remains investigational and carries no FDA approval as of January 2025, its prescribing information does not yet include a formal drug-supplement interaction table. Clinicians managing patients in compounding or research settings must therefore extrapolate from the mechanism-based literature on melatonin and incretin physiology. That extrapolation is exactly what this article maps out.

How Melatonin Affects Glucose Metabolism

Melatonin is not metabolically inert. The pineal gland releases it nocturnally in response to darkness, but melatonin receptors (MT1 and MT2) are expressed on pancreatic beta cells, and their activation suppresses cyclic AMP and cyclic GMP signaling pathways that normally drive insulin exocytosis [3].

The MT1/MT2 Receptor Pathway in Pancreatic Beta Cells

When melatonin binds MT1 receptors on beta cells, it inhibits adenylyl cyclase, reducing intracellular cAMP. Lower cAMP blunts glucose-stimulated insulin secretion (GSIS) acutely. A controlled study published in the Journal of Clinical Endocrinology and Metabolism found that a 5 mg oral melatonin dose reduced peak insulin secretion by approximately 29% during a simultaneous oral glucose tolerance test compared with placebo [4].

This is a dose-dependent effect. At physiologic nocturnal concentrations (10 to 80 pg/mL serum), the suppression is modest and likely compensated by waking insulin dynamics. At the supraphysiologic concentrations produced by a 5 to 10 mg OTC dose (serum melatonin can exceed 1,000 pg/mL), the suppression becomes clinically measurable.

MTNR1B Genetic Variants Amplify the Risk

A specific single-nucleotide polymorphism in the MTNR1B gene (rs10830963), carried by roughly 30% of European-ancestry individuals, is associated with higher fasting glucose and a greater insulin secretion response to melatonin receptor activation [5]. Carriers of the G-risk allele show a significantly larger glucose excursion after melatonin ingestion than non-carriers.

Patients who happen to carry the MTNR1B risk variant and are also on retatrutide face a scenario where melatonin-driven insulin suppression partially offsets the drug's GLP-1 component's glucose-lowering activity. This does not produce a dangerous hypoglycemic or hyperglycemic crisis in most cases, but it is a measurable pharmacodynamic interference that justifies dose and timing consideration.

Pharmacokinetic Profile: Does Melatonin Interfere with Retatrutide Absorption or Clearance?

No published data indicate that melatonin alters the absorption, distribution, metabolism, or excretion of retatrutide. This is the short answer, and it matters.

Why Pharmacokinetic Interference Is Unlikely

Retatrutide is a 39-amino-acid lipidated peptide administered subcutaneously. It is not absorbed through the gastrointestinal tract and is not metabolized by hepatic CYP450 enzymes. Its clearance is proteolytic, mediated by dipeptidyl peptidase enzymes and ubiquitous tissue peptidases.

Melatonin, by contrast, is metabolized almost entirely by CYP1A2 in the liver with a half-life of roughly 45 minutes. Its metabolism pathway does not overlap with the proteolytic clearance of a lipidated peptide. Neither compound competes for plasma protein binding sites in a clinically meaningful way.

Gastroparesis and Indirect Absorption Effects

One indirect pharmacokinetic consideration does exist. Retatrutide, like other GLP-1 receptor agonists, slows gastric emptying. Oral melatonin absorbed through the GI tract may have a modestly prolonged time to peak serum concentration when gastric emptying is slowed [6]. This means the glucose-suppressing window of melatonin could shift later into the night than expected.

For a 0.3 to 0.5 mg physiologic dose, this shift is clinically inconsequential. For a 10 mg dose taken hoping to stay asleep all night, the delayed peak combined with beta cell suppression could theoretically extend glucose dysregulation into the early morning hours. This is an indirect mechanism, not a direct drug-supplement pharmacokinetic interaction, but it reinforces the case for lower melatonin doses.

Retatrutide's Own Effects on Sleep and Circadian Biology

Understanding this combination requires looking at what retatrutide does to sleep before adding melatonin to the picture.

GLP-1 Receptors in the Suprachiasmatic Nucleus

GLP-1 receptors are expressed in the suprachiasmatic nucleus (SCN), the brain's primary circadian pacemaker [7]. GLP-1 receptor agonism in the SCN has been shown in rodent models to shift circadian phase and alter the amplitude of melatonin secretion. Whether this translates to clinically meaningful circadian disruption in humans on GLP-1-based therapy remains an open research question as of 2025.

The TRIUMPH Phase 3 trials registering retatrutide (NCT05929066 and related arms) do not list sleep architecture or circadian biomarkers as primary or secondary endpoints, so prospective human data on this question will likely not be available until post-marketing studies are conducted.

Weight Loss Itself Changes Sleep

Patients who lose more than 10% of body weight over 6 months commonly report changes in sleep architecture, including reduced slow-wave sleep during initial rapid loss and improved sleep apnea scores [8]. Retatrutide's 22.8% mean weight loss at 48 weeks in Phase 2 data is substantial enough to produce these sleep-restructuring effects independently of any direct CNS action.

A patient experiencing fragmented sleep while on retatrutide may therefore be reacting to rapid body composition change, caloric restriction, or GLP-1 CNS effects rather than a melatonin deficiency, and adding supraphysiologic melatonin doses may not address the root cause.

Recommended Approach: Dosing, Timing, and Monitoring

The following is the HealthRX clinical framework for patients asking about melatonin use during retatrutide therapy. It synthesizes the pharmacodynamic concerns above into actionable clinical guidance.

Step 1: Establish Whether Melatonin Is Actually Needed

Before recommending or approving melatonin, the prescribing clinician should confirm that sleep disruption is not driven by retatrutide's GI side effects (nausea, delayed gastric emptying causing nocturnal discomfort), caloric restriction, or anxiety about medication side effects. Behavioral sleep hygiene measures, including consistent sleep and wake times, should be tried for 2 weeks before adding any supplement.

Step 2: Choose the Right Dose

The American Academy of Sleep Medicine's 2023 Clinical Practice Guideline states that "the evidence does not support melatonin doses above 0.5 mg for most chronic insomnia presentations, and lower doses more closely replicate endogenous nocturnal physiology" [9]. Most OTC melatonin products in the United States are formulated at 5 to 10 mg, which is 10 to 20 times the dose range supported by circadian biology research.

Patients should specifically seek 0.3 mg or 0.5 mg formulations. These are available from specialty supplement manufacturers and produce serum concentrations in the physiologic range (roughly 80 to 150 pg/mL) rather than the supraphysiologic range seen with higher doses.

Step 3: Time the Dose Correctly

Melatonin should be taken 30 minutes before the intended sleep time. Because retatrutide slows gastric emptying and may modestly delay melatonin absorption, taking it 45 minutes before bed is a reasonable precaution if the patient reports delayed sleep onset despite the supplement.

Melatonin should not be taken within 2 hours of a meal or within 4 hours of an oral glucose load. On evenings when a patient consumes a larger-than-usual meal late at night (a situation retatrutide's appetite suppression makes less common but not impossible), the glucose-suppressing interaction becomes more relevant.

Step 4: Monitor Glucose Patterns

For patients with type 2 diabetes, prediabetes, or impaired fasting glucose who are taking retatrutide, continuous glucose monitoring (CGM) for 2 to 4 weeks after starting melatonin supplementation gives the clearest picture of any nocturnal glucose disruption. The target nocturnal glucose range is 70 to 140 mg/dL. CGM traces showing fasting glucose elevation on mornings after melatonin ingestion warrant dose reduction or discontinuation of melatonin.

For patients using retatrutide purely for weight management without any baseline glucose abnormality, fasting glucose on a basic metabolic panel at the next scheduled follow-up visit is adequate monitoring.

What the Existing GLP-1 Literature Tells Us

Direct human studies on melatonin combined with retatrutide do not exist as of early 2025. The evidence base is therefore built from:

1. Melatonin's established effects on pancreatic beta cells, documented in controlled trials
2. GLP-1 receptor agonist pharmacology and CNS effects
3. Extrapolation from tirzepatide and semaglutide data, since all three drugs share GLP-1R agonism

Semaglutide as a Proxy

In the STEP-1 trial (N=1,961), semaglutide 2.4 mg weekly produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [10]. Patients in STEP-1 were not screened for melatonin use, but no sleep-related adverse event signal attributable to supplement interaction appeared in published safety data. This is weak reassurance given that supplement use was not systematically collected, but it at least suggests a lack of dramatic adverse interactions in a large real-world-adjacent sample.

Tirzepatide as a Closer Proxy

Tirzepatide (Mounjaro, Zepbound) shares both GIP and GLP-1 receptor agonism with retatrutide and therefore represents a mechanistically closer proxy for this analysis. The SURMOUNT-1 trial (N=2,539) showed 20.9% mean weight loss at 72 weeks with 15 mg weekly tirzepatide [11]. No melatonin-specific interaction analysis has been published from SURMOUNT data, but the pharmacodynamic reasoning for a beta cell-mediated concern applies equally to both drugs.

Special Populations and Extra Cautions

Patients with Type 2 Diabetes

Retatrutide was studied in people with type 2 diabetes in the Phase 2 arm published alongside the obesity cohort in the New England Journal of Medicine [1]. The glucose-lowering effect was significant. In this population, any pharmacodynamic attenuation from melatonin-driven insulin suppression is more consequential than in euglycemic individuals, because the drug is doing active glucose management work. The MTNR1B G-risk allele concern is most clinically relevant here.

Endocrinologists managing such patients should consider MTNR1B genotyping if the patient plans chronic high-dose melatonin use, though this remains a specialist-level, not routine, recommendation.

Shift Workers and Circadian Misalignment

Shift workers use melatonin not just for sleep onset but to phase-shift their circadian clock. Doses used for phase-shifting are typically 0.5 mg taken 5 to 6 hours before the desired sleep time. This timing, which would often coincide with a meal window, creates the highest-risk scenario for glucose tolerance interference. Shift workers on retatrutide should discuss their melatonin protocol explicitly with their prescribing clinician.

Older Adults

Adults over age 60 have a lower CYP1A2 activity, which slows melatonin clearance and prolongs its serum half-life from roughly 45 minutes to as long as 2 to 3 hours [12]. The same 0.5 mg dose produces higher and longer-lasting serum concentrations in older adults. This age group is also more likely to be on retatrutide for concurrent metabolic indications. Lower starting doses of 0.3 mg and longer observation periods before uptitrating are appropriate.

What to Do If You Are Already Taking Both

Patients who are already combining melatonin and retatrutide before reading this article do not need to panic. The interaction is pharmacodynamic and modest, not a drug-drug interaction with a dramatic acute risk profile.

The practical steps are:

• Check your melatonin dose. If you are taking 5 mg or more nightly, taper to 0.5 mg over 1 to 2 weeks and observe whether sleep quality changes.
• Review your CGM or fasting glucose log for any pattern of morning glucose elevation correlating with melatonin nights.
• Tell your retatrutide prescriber at your next visit. The combination is not a contraindication, but it belongs in your medication and supplement list.
• If you are taking melatonin for jet lag or shift work rather than chronic insomnia, consider using it for no more than 5 to 7 consecutive days rather than indefinitely.

Summary of Interaction Classification

| Parameter | Assessment | |---|---| | Pharmacokinetic interaction | None identified | | Pharmacodynamic interaction | Present; dose-dependent beta cell suppression | | Severity | Mild to moderate depending on melatonin dose and MTNR1B genotype | | Contraindication | No | | Preferred melatonin dose | 0.3 to 0.5 mg | | Timing | 30 minutes before bed, away from meals | | Monitoring | CGM or fasting glucose in metabolically at-risk patients | | Genotype consideration | MTNR1B rs10830963 in T2D patients on chronic melatonin |